Building bones with nutraceuticals

Pharmaceutical Journal

Volumn 277, Issue 7409, 2006, Pages 78-83

  Appleton, David ^a   Lockwood, Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CALCIUM ION; CARNITINE; COCONUT OIL; CONJUGATED LINOLEIC ACID; DAIDZEIN; DOCOSAHEXAENOIC ACID; EICOSAPENTANOIC ACID; ESTRADIOL; ESTROGEN; FISH OIL; GAMMA LINOLENIC ACID; GENISTEIN; GLYCITEIN; GLYCOSAMINOGLYCAN; HYDROXYAPATITE; ISOFLAVONE DERIVATIVE; ISOLARICIRESINOL; LIGNAN DERIVATIVE; LINOLEIC ACID; LINOLENIC ACID; NUTRACEUTICAL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PARATHYROID HORMONE; PHYTOESTROGEN; PINORESINOL; POLYUNSATURATED FATTY ACID; SECOISOLARICIRESINOL DIGLUCOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; AUTOCRINE EFFECT; BONE DENSITY; BONE GROWTH; BONE MASS; BONE MATRIX; BONE METABOLISM; BONE REMODELING; CALCIUM ABSORPTION; CALCIUM HOMEOSTASIS; CARNITINE DEFICIENCY; CLINICAL TRIAL; CORTICAL BONE; DRUG DOSE REGIMEN; DRUG POTENTIATION; ENVIRONMENTAL FACTOR; FAT INTAKE; FRACTURE; FRAGILITY FRACTURE; HEREDITY; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PARACRINE SIGNALING; POSTMENOPAUSE OSTEOPOROSIS; TRABECULAR BONE; UNSPECIFIED SIDE EFFECT; WEIGHT BEARING;

EID: 33746425672     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Ferguson N. Osteoporosis in focus. London: Pharmaceutical Press, 2004.
2. Tanna N. Osteoporosis and its treatment. The Pharmaceutical Journal 2005;275:521-2.
3. World Health Organization Scientific Group on the Prevention and Management of Osteoporosis. Prevention and management of osteoporosis: report of a World Health Organization scientific group. Geneva: WHO, 2003.
4. Goldring SR. Inflammatory mediators as essential elements in bone remodelling. Calcified Tissue International 2003;73:97-100.
5. Watkins BA, Li Y, Lippman HE, Feng S. Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism. Prostaglandins Leukotrienes and Essential Fatty Acids 2003;68:387-98.
6. National Osteoporosis Society. What is osteoporosis? Available at: www.nos.org.uk/about.htm. Accessed 28 June 2006.
7. Rapport L, Lockwood B. Nutraceuticals. London: Pharmaceutical Press, 2002.
8. Cardinali DP, Ladizesky MG, Boggio V, Cutrera RA, Mautalen C. Melatonin effects on bone: experimental facts and clinical perspectives. Journal of Pineal Research 2003;34:81-7.
9. Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni JM. Evidence for melatonin synthesis in mouse and human bone marrow cells. Journal of Pineal Research 2000;28:193-202.
10. Tan DX, Manchester LC, Reiter RJ, Qi WB, Zhang M, Weintraub ST, et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochimica et Biophysica Acta 1999;1472:206-14.
11. Roth JA, Kim BG, Lin WL, Cho MI. Melatonin promotes osteoblast differentiation and bone formation. Journal of Biological Chemistry 1999;274:22041-7.
12. Fernandes G, Lawrence R, Sun D. Protective role of n-3 lipids and soy protein in osteoporosis. Prostaglandins Leukotrienes and Essential Fatty Acids 2003;68:361-72.
13. Koyama H, Nakade O, Takada Y, Kaku T, Lau KH. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. Journal of Bone and Mineral Research 2002;17:1219-29.
14. Suzuki N. Hattori A. Melatonin suppresses osteoclastic and osteoblastic activities in the scales of goldfish. Journal of Pineal Research 2002;33:253-8.
15. Ladizesky MG, Boggio V, Albornoz LE, Castrillon PO, Mautalen C, Cardinali DP. Melatonin increases estradiol-induced bone formation in ovariectomised rats. Journal of Pineal Research 2003;34:143-51.
16. Forsling ML. Wheeler MJ. Williams AJ. The effect of melatonin administration on pituitary hormone secretion in man. Clinical Endocrinology 1999;51:637-42.
17. Colucci S, Mori G, Vaira S, Brunetti G, Greco G, Mancini L, et al. L-Carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcified Tissue International 2005;76:458-65.
18. Chiu KM, Keller ET, Crenshaw TD, Gravenstein S. Carnitine and dehydroepiandrosterone sulfate induce protein synthesis in porcine primary osteoblast-like cells. Calcified Tissue International 1999;64:527-33.
19. Corwin RL. Effects of dietary fats on bone health in advanced age. Prostaglandins Leukotrienes and Essential Fatty Acids 2003;68:379-86.
20. Kato I, Toniolo P, Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, et al. Diet, smoking and anthropometric indices and postmenopausal bone fractures: a prospective study. International Journal of Epidemiology 2000;29:85-92.
21. Umegaki K, Hashimoto M, Yamasaki H, Fujii Y, Yoshimura M, Sugisawa A, et al. Docosahexaenoic acid supplementation-increased oxidative damage in bone marrow DNA in aged rats and its relation to antioxidant vitamins. Free Radical Research 2001;34:427-35.
22. Coetzer H, Claasen N, van-Papendorp DH, Kruger MC. Calcium transport by isolated brush border and basolateral membrane vesicles: role of essential fatty acid supplementation. Prostaglandins Leukotrienes and Essential Fatty Acids 1994;50:257-66.
23. Marie PJ. Cellular and molecular alterations of osteoblasts in human disorders of bone formation. Histology and Histopathology 1999;14:525-38.
24. Weiler HA, Fitzpatrick-Wong SC. Modulation of essential (n-6):(n-3) fatty acid ratios alters fatty acid status but not bone mass in piglets. Journal of Nutrition 2002;132:2667-72.
25. Watkins BA, Li Y, Allen KG, Hoffmann WE, Seifert MF. Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. Journal of Nutrition 2000;130:2274-84.
26. Sakaguchi K, Morita I, Murota S. Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. Prostaglandins Leukotrienes and Essential Fatty Acids 1994;50:81-4.
27. Lorenzini A, Bordoni A, Spano C, Turchetto E, Biagi PL, Hrelia S. Age-related changes in essential fatty acid metabolism in cultured rat heart myocytes. Prostaglandins Leukotrienes and Essential Fatty Acids 1997;57:143-7.
28. Bhathena SJ, Berlin E, Judd JT, Kim YC, Law JS, Bhagavan JN, et al. Effects of n3 fatty acids and vitamin E on hormones involved in carbohydrate and lipid metabolism in men. American Journal of Clinical Nutrition 1991;54:684-88.
29. Park Y, Albright KJ, Liu W, Storkson JM, Cook ME, Pariza MW. Effect of conjugated linoleic acid on body composition in mice. Lipids 1997;32:853-8.
30. Cusack S, Jewell C, Cashman KD. The effect of conjugated linoleic acid on the viability and metabolism of human osteoblast-like cells. Prostaglandins Leukotrienes and Essential Fatty Acids 2005;72:29-39.
31. Kelly O, Cusack S, Jewell C, Cashman KD. The effect of polyunsaturated fatty acids, including conjugated linoleic acid, on calcium absorption and bone metabolism and composition in young growing rats. British Journal of Nutrition 2003;90:743-50.
32. Doyle L, Jewell C, Mullen A, Nugent AP, Roche HM, Cashman KD. Effect of dietary supplementation with conjugated linoleic acid on markers of calcium and bone metabolism in healthy adult men. European Journal of Clinical Nutrition 2005;59:432-40.
33. Belury MA, Mahon A, Banni S. The conjugated linoleic acid (CLA) isomer, t10c12-CLA, is inversely associated with changes in body weight and serum leptin in subjects with type 2 diabetes mellitus. Journal of Nutrition 2003;133:257S-260S.
34. Kotecha N, Lockwood B. Soy-relieving the symptoms of menopause and fighting osteoporosis. Pharmaceutical Journal 2005;275:483-7.
35. Jones M. Soya and osteoporosis. NutraCos 2003;26-28.
36. Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism 2003;88:4740-7.
37. Dang ZC, Papapoulos S, Lowik C. Phytoestrogens enhance osteogenesis and concurrently inhibit adipogenesis. Journal of Nutrition 2002;132:617S.
38. Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. American Journal of Clinical Nutrition 2003;78:593S-609S.
39. Ward WE, Yuan YV, Cheung AM, Thompson LU. Exposure to purified lignan from flaxseed (Linum usitatissimum) alters bone development in female rats. British Journal of Nutrition 2001;86:499-505.
40. Zhang X, Shu XO, Li H, Yang G, Li Q, Gao YT, et al. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Archives of Internal Medicine 2005;165:1890-5.
41. Brooks JD, Ward WE, Lewis JE, Hilditch J, Nickell L, Wong E, et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. American Journal of Clinical Nutrition 2004;79:318-25.
42. Picherit C, Coxam V, Bennetau-Pelissero C, Kati-Coulibaly S, Davicco MJ, Lebecque P, et al. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. Journal of Nutrition 2000;130:1675-81.
43. Setchell KD. Absorption and metabolism of soy isoflavones-from food to dietary supplements and adults to infants. Journal of Nutrition 2000;130:654S-5S.
44. Barnes S. Phyto-oestrogens and osteoporosis: what is a safe dose? British Journal of Nutrition 2003;89:S101-8.